Select your timezone:

Kidney - Diagnostics 1

Tuesday September 13, 2022 - 16:25 to 17:25

Room: C3

332.8 Optimized use of erythropoietin stimulating agents in kidney recipients with post-transplant anemia: a prospective randomized controlled trial

Osama Ashry Gheith, Egypt

Mansoura university



I am Dr. Osama Ashry Ahmed Gheith, who graduated in 1987 from Mansoura faculty of medicine, Egypt. I have held an MD degree in Internal Medicine and Nephrology since 2003. I have been trained at Mansoura urology and nephrology center, Mansoura University, Egypt from 1991 till 2008 when I join the work at Hamed Al-Essa organ transplant center.

I am a member of the following societies: International Society of Nephrology (ISN), European Dialysis Transplantation Association (EDTA), African Association of Nephrology (AFRAN), Arab Society of Nephrology, and Egyptian Society of Nephrology (ESN).

I have long experience with all nephrology activities including all dialysis modalities, medical care of more than 3500 renal transplant recipients, and surgical Skills of importance in the field of nephrology as vascular access creation, PD catheter insertion, and renal biopsies. Moreover, I am interested in training and supervising Junior Staff in nephrology and renal transplant (in Egypt, Yemen, and Kuwait).

I have completed the NIH Web-based training course “Protecting Human Research Participants”. I am interested in research work and have over 12 research projects ongoing in the department. I am an author and/or co-author of over 85 publications in peer-reviewed international journals. In addition to several abstracts in many Middle East and international conferences. I am interested in the field of immunosuppression in renal transplantation, post-transplant diabetes, infection, and anemia.

I won some of the research prizes with the special concern of Emirates medical association –Nephrology Society EMAN YOUNG INVESTIGATOR AWARD –during the 12th congress of the Arab society of nephrology and renal transplantation 2014, 6th ISN EMAN Update Course in Nephrology 2014, 10-13December 2014 Dubai, UAE; one of the top 5 posters presented in ESNT 2018 (impact of HLA DR mismatch in elderly renal transplant recipients regardless donor sources: single-center experience from the middle east) and one of the top 5 posters presented in ESNT 2019 (Screening for BK viremia/viruria and the Impact of Management of BK Virus Nephropathy in Renal Transplant Recipients).


Optimized use of erythropoietin stimulating agents in kidney recipients with post-transplant anemia: a prospective randomized controlled trial

Torki Al-Otaibi 1, Medhat A. halim1, Osama Gheith1,2, Ayman M. Najeeb1,2, Hasanein Abo-Atteya1, Tarek Mahmoud1, Nair Prasad1, Ahmed Fathy1, Mohamed Balaha 1, Narayanam Nampoory 1.

1Nephrology , Otc, Kuwait, Kuwait; 2Nephrology , MUNC, mansoura, Egypt

Objectives: Many studies suggested that chronic allograft nephropathy might progress faster in patients with PTA, but whether full correction of anemia improves renal outcomes is unknown.

Aim of the work: We aimed to assess the impact of full correction of chronic anemia in renal transplant recipients with stable graft function on patient and graft outcome along one year follow-up.
Patient and methods: We enrolled 247 kidney recipients with stable graft function to be assessed for anemia. Eligible patients were randomized to achieve target hemoglobin between 11:12 g/dl (group 1, n=183), or 13:15 g/dl (in group 2, n=64) using erythropoietin receptor stimulating agents(ESA). Monthly clinical and laboratory evaluation of kidney graft function was carried out. Quality of life was assessed at the start and 12 months.

Results: More females were found in group 1(68.9%) vs. (50%) in group 2 (p=0.007), and the original disease was chronic glomerulonephritis (37.5%) followed by diabetic nephropathy (DN) (15.7%)in group2 ; but DN patients predominate in group 1(p= 0.005). The studied groups were comparable regarding pre-transplant co-morbidities. Most patients received thymoglobulin as induction and most of them were maintained on cyclosporine. We did not find any significant difference between the two groups concerning post-transplant diabetes, BK viremia or malignancies (p >0.05), however better graft function was observed in group 2 at 6 months (p< 0.05). We found that required ESA doses were significantly higher in patients of group 1 from the 6th month. Group 1 showed higher mean blood pressure (p=0.003) while group 2 showed higher mean albumin (p<0.05). Graft outcome was comparable in both groups (p=0.125), but mortality cases were significantly higher in group 1 (16 cases, 8.7%)(p=0.005).

Conclusion:  Full correction of PTA in renal transplant recipients had no positive impact on graft outcome but it was associated with better patient survival possibly due to improved cardiovascular risk.

Presentations by Osama Ashry Gheith

Social Media Promotion Image

right-click to download

© 2024 TTS 2022